logo
Share SHARE
FONT-SIZE Plus   Neg

E-Therapeutics Granted Approval For Phase I Trials Of Anti-cancer Drug ETS2101

Biotechnology company e-Therapeutics Plc (ETX.L) Thursday announced that its plans for Phase-1 trials of its anti-cancer drug ETS2101 have received approvals from the regulatory authorities both in the UK and in the US.

Following the receipt of approvals, the company reaffirmed that enrolment of patients for the Phase-1 trial in both the US and the UK would be commencing shortly.

Professor Malcolm Young, CEO of e-Therapeutics, said: "We remain on track to report the first data from cancer trials with ETS2101 and to advance three further drugs into the clinic by the end of this year."

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Women's specialty-clothing retailer J. Jill Inc. said it has launched an initial public offering of 11.67 million shares of its common stock. All shares are being sold by an existing stockholder and J. Jill will not receive any proceeds from the offering. Long queues at peak dining hours at Wendy's may be a history, as the company is planning to introduce automated self ordering kiosks at its more than 1000 retail locations by this year end. The automation will also help in cutting labor costs. Canadian music retail chain Sunrise Records said it plans to take over 70 retail spaces in Canada being vacated by HMV Canada, the industry's largest retailer. The new brick and mortar locations are in malls across Canada. However, Sunrise's expansion comes as people are increasingly shifting to streaming options for music and videos rather than buying tangible, touchable albums.
comments powered by Disqus
Follow RTT